This article looks at the 13 Best German Stocks to Invest in Now.
European shares declined on Friday amid losses in bank and mining-related stocks, as investors shifted their focus to the July 9 deadline for trading partners to reach a deal with the United States.
The pan-European STOXX 600 index was down 0.5%, while other regional indexes also dipped, including Germany’s DAX (-0.60%).
However, on a year-to-date basis, the DAX index has gained 19.48%, comfortably outperforming its US counterparts, driven by a robust show by the country’s defense stocks, as European governments unlocked billions to supercharge their militaries.
On June 24, the German cabinet approved a draft budget for 2025 and a budget framework for the following year, which includes heavy investments to stimulate economic growth and further increase the country’s defense spending.
Finance Minister Lars Klingbeil stated the following on the draft budget:
“With this budget and the 500-billion-euro investment fund, we are setting in motion what we need now to ensure new economic strength, make our country modern and future-proof and to enable safe living in Germany in the future as well.”
With that said, let’s now head over to the list of the 13 best German stocks to invest in.
A financial trader on the floor of the Stock Exchange, intently watching the markets.
Methodology
For this article, we identified German stocks listed on American exchanges and ranked them in ascending order of the number of hedge fund investors having a stake in them, based on Insider Monkey’s database of over 1,000 prominent hedge funds as of Q1 2025. In cases where two or more stocks were tied on hedge fund sentiment, we used market cap as a tiebreaker between them.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
13 Best German Stocks to Invest in Now:
13. Anbio Biotechnology (NASDAQ:NNNN)
Number of Hedge Fund Holders: 1
Anbio Biotechnology (NASDAQ:NNNN) is one of the 13 Best German Stocks to Invest in Now. The company is engaged in the development of medical technology and the provision of in vitro diagnostics products.
It was incorporated in 2021 and is based in Frankfurt. Anbio Biotechnology (NASDAQ:NNNN) had its initial public offering in February this year on the NASDAQ Global Market, with shares trading under the ticker ‘NNNN’.
The company announced receiving $8 million in aggregate gross proceeds from the offerings, which it intends to use for sales growth, expansion of the distribution network in selected markets, research & development, and other corporate purposes.
Anbio Biotechnology (NASDAQ:NNNN)’s NASDAQ debut has garnered strong investor interest, resulting in a nearly 600% surge from its IPO price of $5. The company is also currently pivoting from pandemic tests and is expanding into oncology, cardiovascular, and infectious diseases.
However, still a major chunk of Anbio Biotechnology (NASDAQ:NNNN)’s revenue comes from COVID-related in vitro diagnostics products, which could become a significant headwind in the short run for the company with the pandemic receding.
12. Evotec SE (NASDAQ:EVO)
Number of Hedge Fund Holders: 1
Evotec SE (NASDAQ:EVO) is among the 13 Best German Stocks to Invest in Now. The company’s shares have gained over 9% in the past month, as of the close of business on July 2, amid positive recent developments.
On June 25, Evotec SE (NASDAQ:EVO) announced that it had joined the NURTuRE-AKI consortium to investigate acute kidney injury (AKI) and advance drug discovery through multi-omics approaches. Under this initiative, the company will identify key factors that cause AKI and develop innovative and effective treatments for patients based on a molecular understanding of the disease.
Earlier in the month, Evotec SE (NASDAQ:EVO) held its annual general meeting for 2025, in which shareholders approved, with a great majority, most of the proposals put forward by the management. Around 46.45% of the registered share capital was represented in the meeting, in which CEO Dr Christian Wojczewski also discussed the company’s current situation and strategic outlook.
Investor sentiment has also been strengthened by Warburg Research’s recent coverage of the stock on June 26, in which analyst Robert-Jan van der Horst reiterated a Buy rating for Evotec SE (NASDAQ:EVO), with its price target at €11.30.
Evotec SE (NASDAQ:EVO) is a drug discovery company that focuses on developing new pharmaceutical products through the integration of breakthrough science, advanced technology, and AI-driven innovation. In May this year, it received a $2.5 million grant from the Gates Foundation to support the development of next-generation tuberculosis treatments.